Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy
Open Access
- 18 March 2020
- journal article
- case report
- Published by Springer Nature in CEN Case Reports
- Vol. 9 (3) , 237-242
Abstract
Fabry disease is an X-linked inherited lysosomal storage disorder caused by a deficiency of α-galactosidase A activity, resulting in the intracellular accumulation of globotriaosylceramide and related glycosphingolipids. The phenotypes of Fabry disease in both males and females are grouped into two categories: the classical type and the late-onset type. The classical type shows general symptoms including angiokeratoma(s), acroparesthesia, hypohidrosis, corneal opacity, and gastrointestinal symptoms from an early age. The late-onset type shows cardiac or renal (or both) symptoms from a late age. We present herein the clinical course and pathological findings of two late-onset hemizygous Fabry patients after the initiation of enzyme replacement therapy (ERT), along with their mulberry cell counts during treatment. One patient’s case was a renal-variant type without general symptoms; he showed stable renal function and mild proteinuria but little histological improvement with no change in the mulberry cell count during ERT. The other patient had a cardiac-variant type with renal pathological abnormality. He achieved a mild improvement of renal pathological findings, and his mulberry cell count gradually decreased during the treatment. These findings indicate that monitoring the mulberry cell count might help assess the efficacy of ERT, as a renal pathology tool.Keywords
This publication has 15 references indexed in Scilit:
- Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry diseaseCEN Case Reports, 2017
- Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyJournal of the American Society of Nephrology, 2016
- A Renal Variant of Fabry Disease Diagnosed by the Presence of Urinary Mulberry CellsInternal Medicine, 2016
- Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapyJournal of Medical Genetics, 2015
- Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST)Clinical and Experimental Nephrology, 2015
- Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysisMolecular Genetics and Metabolism Reports, 2015
- Agalsidase Benefits Renal Histology in Young Patients with Fabry DiseaseJournal of the American Society of Nephrology, 2013
- Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)Nephrology Dialysis Transplantation, 2009
- Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry DiseaseJournal of the American Society of Nephrology, 2007
- Fabry's Disease: Alpha-Galactosidase DeficiencyScience, 1970